Incretins continue to dominate obesity conferences

Obesity is far and away the industry’s biggest growth area, but there’s a challenge appearing on the horizon: the field has few new targets that could expand treatment beyond incretin-based therapies.

GLP-1R-based drugs deliver strong efficacy for many patients, but their side effect profile can make it challenging for patients to stay on therapy long term...